2758431-90-0

Thalidomide-containing building block with PEG2-linker and azide function group, which can be conjugated to alkyne-functionalized linkers and target protein ligands through click chemistry reactions.

Proteolysis targeting chimeras (PROTACs) are cell-permeable heterobifunctional molecules that can remove specific proteins from the cell. One end of such molecule contains a ligand to bind to the target, and the second end recruits the E3 ligase complex. Close proximity results in substrate polyubiquitination and subsequent protein degradation by cellular proteasome.

There are several types of E3 ligases that are practically suitable for such a purpose. Thalidomide is the ligand capable of recruiting Cereblon (CRBN) E3 ligase.

Thalidomide 4'-ether-PEG2-azide is a click chemistry modified cereblon (CRBN) inhibitor Thalidomide (HY-14658). Thalidomide 4'-ether-PEG2-azide contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing alkynyl groups. Thalidomide 4'-ether-PEG2-azide can be used as a ligand of E3 ubiquitin ligase and Linker conjugates (E3 Ligase Ligand-Linker Conjugates) for the synthesis of PROTACs[1].

Thalidomide 4'-ether-PEG2-azide is a functionalized cereblon ligand for PROTAC? research and development; incorporates an E3 ligase ligand plus a PEG2 linker with azide terminal ready for conjugation to a target protein ligand.

Store at -20°C

[1] Fischer ES, et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Nature. 2014 Aug 7;512(7512):49-53. DOI:10.1038/nature13527